MSN
GenericsMSN is a generic drug manufacturer focused on Oncology, Cardiovascular, Neurology. Key products include OLUMIANT.
MSN's Key Drugs
MSN's core commercial portfolio centers on DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE, OLUMIANT, SACUBITRIL AND VALSARTAN, spanning Oncology and Cardiovascular — its most strategically important drugs approved in the last 15 years.
Type 2 Diabetes Mellitus
Rheumatoid Arthritis
Heart Failure
Type 2 Diabetes
Hypertension
MSN's Recent FDA Approvals
MSN secured 3 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
MSN's Therapeutic Areas
MSN's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Cardiovascular, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
MSN's Top Competitors
MSN's closest competitors by therapeutic-area and drug-target overlap include Novartis, GE HEALTHCARE, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
MSN Pipeline Snapshot
Active clinical trials for MSN across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE leads revenue
- • 5 key drugs tracked
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (7)
Discontinued (1)
Company Info
- First Approval
- 2017-09-22
- Latest
- 2026-06-12
- Applications
- 114